T-lymphoblastic Lymphoma Clinical Trial
Official title:
Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
Main research purposes: To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL. Secondary research purposes: To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory T-LBL/ALL. Exploratory research purpose： 1. To explore the immunogenicity of SENL101； 2. T cell NK cell recovery time after treatment； ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04620655 -
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
|
N/A | |
| Not yet recruiting |
NCT06434467 -
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
|
Phase 3 | |
| Recruiting |
NCT04582487 -
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
|
N/A | |
| Suspended |
NCT04828174 -
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT05068401 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03558412 -
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
|
Phase 4 | |
| Recruiting |
NCT05576532 -
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
|
Phase 2 | |
| Withdrawn |
NCT04860817 -
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
|
Early Phase 1 | |
| Recruiting |
NCT04004637 -
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT06376721 -
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
|
Phase 1/Phase 2 |